The molecular basis for the systolic and diastolic dysfunction characteristic of end-stage heart failure in humans remains poorly understood. It has been proposed that both abnormal calcium handling and defects in the contractile apparatus may contribute to the myocardial dysfunction. Two channels, the calcium release channel (CRC) or ryanodine receptor of the sarcoplasmic reticulum (SR), and the slow calcium channel or dihydropyridine receptor (DHPR) of the transverse tubule, play key roles in regulating intracellular calcium concentration and in excitation-contraction (E-C) coupling in the heart. The DHPR serves as the voltage sensor and plasma membrane calcium channel resulting in activation of the CRC during E-C coupling in heart muscle. In this study, we investigated the levels of CRC expression in several forms of end-stage heart failure in humans. A cardiac CRC cDNA was cloned from rabbit and used as a probe for Northern blot analyses to determine mRNA levels in the left ventricles of normal (n=4) and cardiomyopathic (n=34) human hearts from patients undergoing cardiac transplantation. Compared with normal patients, patients with ischemic cardiomyopathy (n=18) showed a 28% decrease in CRC mRNA levels (p<0.025) and patients with idiopathic dilated cardiomyopathy (n=14) a nonsignificant 12% increase. In these same hearts, a-actin levels were unchanged in end-stage heart failure, as has been previously reported. This is the first report indicating that the expression of the CRC mRNA is abnormal in end-stage human heart failure. The decreased expression of the CRC found specifically in patients with ischemic myopathy (but not idiopathic dilated cardiomyopathy) may, in part, explain differences in calcium handling and response to therapy observed among patients with different forms of cardiomyopathy. Decreased CRC expression could be related to abnormal contractile function in cardiomyopathic muscle resulting from ischemic insult. (Circulation Research 1992;71:18-26) KEY WoRDs * idiopathic dilated cardiomyopathy channel * mRNA * ryanodine receptor T Nhe calcium release channel (CRC) or ryanodine receptor of the sarcoplasmic reticulum (SR) is a large (565-kd) protein that forms the foot structure associating the SR with the transverse tubule
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The molecular basis for the systolic and diastolic dysfunction characteristic of end-stage heart failure in humans remains poorly understood. It has been proposed that both abnormal calcium handling and defects in the contractile apparatus may contribute to the myocardial dysfunction. Two channels, the calcium release channel (CRC) or ryanodine receptor of the sarcoplasmic reticulum (SR), and the slow calcium channel or dihydropyridine receptor (DHPR) of the transverse tubule, play key roles in regulating intracellular calcium concentration and in excitation-contraction (E-C) coupling in the heart. The DHPR serves as the voltage sensor and plasma membrane calcium channel resulting in activation of the CRC during E-C coupling in heart muscle. In this study, we investigated the levels of CRC expression in several forms of end-stage heart failure in humans. A cardiac CRC cDNA was cloned from rabbit and used as a probe for Northern blot analyses to determine mRNA levels in the left ventricles of normal (n=4) and cardiomyopathic (n=34) human hearts from patients undergoing cardiac transplantation. Compared with normal patients, patients with ischemic cardiomyopathy (n=18) showed a 28% decrease in CRC mRNA levels (p<0.025) and patients with idiopathic dilated cardiomyopathy (n=14) a nonsignificant 12% increase. In these same hearts, a-actin levels were unchanged in end-stage heart failure, as has been previously reported. This is the first report indicating that the expression of the CRC mRNA is abnormal in end-stage human heart failure. The decreased expression of the CRC found specifically in patients with ischemic myopathy (but not idiopathic dilated cardiomyopathy) may, in part, explain differences in calcium handling and response to therapy observed among patients with different forms of cardiomyopathy. Decreased CRC expression could be related to abnormal contractile function in cardiomyopathic muscle resulting from ischemic insult. (Circulation Research 1992;71: [18] [19] [20] [21] [22] [23] [24] [25] [26] KEY WoRDs * idiopathic dilated cardiomyopathy channel * mRNA * ryanodine receptor T Nhe calcium release channel (CRC) or ryanodine receptor of the sarcoplasmic reticulum (SR) is a large (565-kd) protein that forms the foot structure associating the SR with the transverse tubule * ischemic cardiomyopathy * calcium release (T tubule) in cardiac and skeletal muscle. The CRC is coupled by an as yet unknown mechanism to the dihydropyridine receptor (DHPR) of the T tubule during excitation-contraction (E-C) coupling in striated muscle."2 Both calcium channels are involved in the regulation of intracellular calcium during diastolic and systolic cycling in the heart. 3 The release and reuptake of Ca21 is also controlled by other calcium-handling proteins, including the Ca24-ATPases, Ca>2 channels, and Ca2 binding proteins found within the cell.4 It has been proposed that alterations in the expression, regulation, or function of these proteins may result in diastolic and systolic dysfunction of the myocardium observed in end-stage heart failure.5 Several studies have documented abnormal calcium homeostasis in the failing myocardium.6-8 Recent clinical trials have documented adverse effects on patients with heart failure treated with organic calcium channel blockers.9-'2 Previous studies found that the expression of the SR Ca'-ATPase5"3 and the DHPR'3 were decreased in endstage human heart failure.
The skeletal and cardiac isoforms of the CRC have been cloned and their primary structure determined in rabbit and human skeletal muscle14-16 4nd in rabbit heart. 17 The cardiac CRC was found to be homologous to, but distinct from, the skeletal form (-66% homology). The skeletal and cardiac CRC cDNAs both encode polypeptides with a mass of 565 kd. Four of these 565 kd polypeptides form the 2.3 million Dalton junctional channel complex that includes the calcium release channel of the SR and the "foot structure" spanning the gap between the SR and the T tubule.18-21 To date, little is known about the regulation of the expression of the CRC in human heart failure. The goal of the present study was to characterize possible alterations in expression of the major intracellular calcium release channel involved in E-C coupling in cardiac muscle from patients with end-stage heart failure. CRC mRNA abundance was determined in left ventricular (LV) myocardial samples from 34 patients with end-stage heart failure and four normal persons (controls). Patients with end-stage heart failure were divided into two major subgroups, those with ischemic (ICM) and those with idiopathic dilated cardiomyopathies (IDCM). CRC mRNA levels were significantly decreased in the subgroup with ICM (but not in patients with IDCM). This decrease in CRC expression was not caused by a generalized decrease in myocardial mRNAs, since the a-actin levels were unchanged, in agreement with a previous report by Boheler et al.22 
Materials and Methods Patients
We analyzed data from 34 patients with end-stage heart failure undergoing cardiac transplant surgery at Brigham and Women's Hospital, Boston, and four control patients free of cardiovascular pathology who were organ donors but who had been rejected as cardiac transplant donors. The subjects included 18 patients with coronary artery disease (ischemic cardiomyopathy [ICM]), two with hypertrophic cardiomyopathy, and 14 with idiopathic dilated cardiomyopathy (IDCM). This study was approved by the Committee for the Protection of Human Subjects from Research Risks at the Brigham and Women's Hospital. Clinical characteristics of the patients are shown in Table 1 . There were no significant differences in any of the clinical parameters recorded in this study between the major subgroups of patients with end-stage heart failure, ICM, and IDCM. At the time of transplantation, hearts were explanted and quickly weighed, and a piece (1-2 g) of myocardium was excised from the LV free wall and immediately immersed in liquid nitrogen. LV samples were obtained from areas that were not macroscopically scarred. All samples were taken from the anterior free wall of the left ventricle near the apex of the heart. Care was taken to obtain samples from the same region of each heart. In cases where infarcts in the distribution of the left anterior descending artery had resulted in scar formation at the apex, samples were obtained from regions as close to the apex as possible outside the left anterior descending artery distribution. The regions free of scarring in the ICM patients were not chosen randomly, but rather dilated cardiomyopathic samples or from the closest region at the apex that was free of scar tissue.
cDNA Probes
The cardiac CRC cDNA probe used for Northern blot analysis was cloned from rabbit heart total RNA essentially as previously described. 23 Sense and antisense primers, CR-4860S (GCAGTGTTTG-GATCCTCTGC) and CR-5440A (GCACAAAGAG-GAATTCGGTGG), respectively, were designed based on the published sequence for the rabbit heart CRC17 (numbers designating each oligonucleotide refer to the position in the published sequence). First-strand cDNA was synthesized using 1 ,ug of total rabbit heart RNA and 2 pmol of antisense primer with avian myeloblastosis virus reverse transcriptase at 42°C for 1 hour. Forty cycles of polymerase chain reaction with Taq DNA polymerase (Perkin-Elmer Cetus) were then performed on 0.1% of the products of first-strand cDNA synthesis with 20 pmol of each primer through use of the following parameters: 1 minute denaturation at 94°C, 2 minutes annealing at 55°C, and 1 minute extension at 72°C. The polymerase chain reaction products were separated from primers on low-melt agarose gels, and a 580-bp cDNA product was excised, purified, digested with EcoRI and BamHI, and subcloned into pBluescript (Stratagene, La Jolla, Calif.). This cDNA clone, HCRC1, was sequenced with the ABI 370 automated sequenator using the M13 forward and reverse primers and shown to correspond to nucleotides [5027-5647] of the cDNA encoding the rabbit cardiac CRC. The actin probe was pAC 269 from chicken skeletal muscle a-actin.24 This probe recognizes both muscle specific (smooth, skeletal, and cardiac a-actins) and nonmuscle (f3 and y) actin isoforms. The glyceraldehyde-3-phosphate-dehydrogenase probe (GAPDH) was a 1.3 kb Pst I fragment from clone pUC-GAPDH13 containing the entire coding region and part of the 3' untranslated region of the rat GAPDH. 25 The SR Ca2' ATPase probe was a 0.7 kb Pst I fragment corresponding to the carboxyl terminus and the 3' untranslated region, this cDNA hybridizes specifically to the rabbit cardiac/slow twitch skeletal muscle SR Ca2' ATPase.26 All probes were uniformly labeled with random primers using Klenow and a_p32 dCTP to a specific activity of > 109 cpm/,g.
RNA Preparation and Northern Blot Analysis
Total cellular RNA was purified from human ventricular tissue samples through use of the lithium chloride/ urea method. 27 The RNA was quantitated by spectrophotometry at 260 nm, and the ratio of absorbance at 260 nm to that at 280 nm was greater than 1.8 for all samples. Total cellular RNA was size fractionated on formaldehyde/agarose gels run at 30 mA overnight to provide resolution of high molecular weight mRNAs. RNA transfer onto nitrocellulose filters was conducted overnight through use of lOx SSC transfer buffer. Gels were photographed before and after transfer, and nitrocellulose filters were photographed after transfer to confirm transfer efficiency of the 28s and 18s ribosomal RNAs. Using these transfer conditions no residual ribosomal RNAs were detected in the gels after transfer. The filters were then baked at 80°C in a vacuum oven for 2 hours were all either in the same region as the normal and and prehybridized ovemight in a buffer containing 1 X Denhardt's solution (0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), 5 x SSC (lx =0.15 M NaCI/0.015 M sodium citrate, pH 7.0), 0.025 M sodium phosphate (pH 7.4), sonicated calf thymus DNA (50 mg/ml), 0.1% SDS, and 50% (vol/vol) formamide. Blots were hybridized with cDNA probes in the same buffer mixture overnight at 42°C. The cDNA probes for each individual mRNA species were labeled once, and the same labeled probe was hybridized to all filters simultaneously to avoid potential differences in specific activity of the labeled probes. Filters were washed simultaneously to a final stringency of 0.2x SSC/0.1% SDS at 65°C for 15 minutes. Six individual blots containing all the samples for this study were hybridized. RNA samples for normal, ICM, and IDCM patients were loaded onto each gel to avoid potential bias caused by variability in the efficiency of transfer of a particular gel or region of a gel. Each filter was exposed for three different exposure times to obtain signals in the linear range for densitometric analysis of each mRNA species. Exposure was at -80°C on x-ray films (X-OMAT AR, Eastman Kodak, Rochester, N.Y.) with a single intensifying screen. Relative amounts of mRNA were determined by using a Xerox scanner with MACIMAGE software. Densitometric analysis was performed using Image 1.36 software on a MacIntosh IIcx that included an algorithm to determine whether the exposure is in the linear range (a density signal <200 indicates exposure in the linear range). All of the signals used for calculations of mRNA quantities were in the linear range. Each densitometric score for the CRC and a-actin mRNAs was then normalized by dividing its optical density with the corresponding GAPDH optical density as an internal control. The mean value for this ratio for the normal group was set at 1.0. Each CRC densitometric score was also normalized to a-actin optical density as an additional internal control.
Controls for RNA degradation and the amount of RNA transferred to each filter included 1) ethidium bromide visualization of the 28s and 18s ribosomal RNAs on the filters; 2) comparison of Northern blot analyses with slot blot results (see "Results"); 3) qualitative analysis of the CRC mRNA signals which were single bands without low molecular weight streaking in the lanes, which would have indicated degradation; 4) control hybridizations to a-actin, and GAPDH probes that demonstrated that the levels of these messages were unchanged between normal and cardiomyopathic samples. To determine that quantitation of mRNAs on Northern blots was not biased by inefficient transfer of mRNAs, slot blots were performed on selected RNA samples (four normal, four ICM, and four IDCM patients). Total RNA was denatured in 50% formamide, 7% formaldehyde, and 1 x SSC by heating at 65°C for 15 minutes followed by cooling on ice. Serial amounts (2.5 gig and 5 gg) of each sample examined were loaded in duplicate (four slots for each RNA sample) on a slot blot apparatus (Bethesda Research Laboratories) and blotted to nitrocellulose. These filters were hybridized to CRC and GAPDH cDNA probes as described above. Autoradiograms in which there was a linear decrease in signal corresponding to the amount of RNA loaded were quantitated by scanning and determining density of signal as described above. Normalized CRC mRNA levels for these 12 samples examined by slot blots were compared with those obtained by Northern blot analyses (see "Results").
Statistical Analysis
All data are expressed as mean+1 SD. Statistical differences were calculated using the unpaired Student's t test, and the p<0.05 level was considered significant. Table 1 summarizes the major clinical characteristics of the patients with end-stage heart failure. Patients underwent clinical evaluations at the Brigham and Women's Hospital. There was no significant difference between the ICM and IDCM groups in terms of mean age (46±10 versus 40±16 years), mean heart weight (474±87 versus 497±102 g), mean cardiac index (1.8±0.6 versus 1.7±0.5 I/minIm2), mean pulmonary capillary wedge pressures (29+ 7 versus 24+ 10 mm Hg), and mean left ventricular end-diastolic pressure (29±9 versus 25±9 mm Hg). Expression of the Sarcoplasmic Reticulum Calcium Release Channel and Calcium ATPase mRNAs in Heart Failure Figure 1 shows representative lanes from Northern blot analyses of human left ventricular RNA hybridized to a probe specific for the cardiac CRC mRNA. In all RNA samples, the HCRC1 probe hybridized to a single mRNA species of -16 kb. Nonspecific hybridization (e.g., to ribosomal RNAs) was not observed. Figure 2 shows Northern blot analyses of representative total RNA samples from human LVs hybridized to probes for the cardiac CRC, a-actin, and GAPDH. Each probe hybridized to a single mRNA species in human myocardial total RNA. The relative decrease in CRC mRNA accumulation in the hearts with ICM is evident. There were no significant differences in the levels of GAPDH mRNA between normal (1.55±0.25), ICM (1.54±0.34), and IDCM (1.32+0.31) hearts. Moreover, ca-actin mRNA levels were not significantly altered between normal (2.12±0.37), ICM (2.0±0.42), and IDCM (1.87±0.38) RNA samples. gg) and patients with heart failure due to ischemic cardiomyopathy (ICM, 30 gg), or idiopathic dilated cardiomyopathy (IDCM, 20 gg) was size fractionated on a formaldehydeagarose gel and blotted to nitrocellulose. Blots were hybridized to a-32P-labeled HCRCJ (see "Materials and Methods").
Results

Clinical Data
This cardiac calcium release channel cDNA probe identifies a single 16 kb mRNA (28s and 18s ribosomal RNAs are used as size markers). Note that the intensities of the bands in each lane do not reflect the relative levels of calcium release channel mRNA present in the respective heart tissues because different amounts of RNA were added in each lane to optimize signals in order to demonstrate that only one mRNA species is detected with the probe. tained by densitometric scanning. The CRC and a-actin mRNA levels were normalized to the GAPDH level for each sample. Figure 3 is a summary of the CRC and a-actin expression data. The CRC mRNA (normalized to GAPDH mRNA levels) was decreased by 28% in the patients with ICM (n=18, p<00.25) compared with normal patients and by 46% (p<0.005) compared with those with IDCM (Table 2 and Figure 2 ). In the patients with IDCM (n 14) there was a nonsignificant increase in CRC abundance of 12% compared with normals. Two patients with HCM also showed a decrease in CRC mRNA abundance, but the patient sampling was too small to assess the significance of this finding (data not shown). The CRC mRNA (normalized to a-actin) was decreased by 28% in the patients with ICM (n =18, p<0.025) compared with normal patients and by 48% (p<0.01) compared with IDCM patients. In the IDCM patients (n=14) there was a nonsignificant increase in CRC mRNA abundance of 18% compared with normal patients. We also observed a 44% decrease in normalized Ca2'-ATPase mRNA levels in the LVs from ICM patients (n=18, p<O.00l) compared with normal patients. There was a similar 56% decrease in normalized Ca2'-ATPase mRNA levels in LVs from patients with IDCM (n 14, p<0.001) compared with normal pa-NL CRC 1CM 1-: FIGURE 2. Calcium release channel mRNA levels in the left ventricle of normal patients (NL) compared with patients with end-stage heart failure caused by ischemic cardiomyopathy (ICM) or idiopathic dilated cardiomyopathy (IDCM). Representative Northern analyses from individual patients are shown. In all RNA samples, the HCRC1 probe hybridized to a single mRNA species of -16 kb, the a-actin probe to a band at -1.6 kb and the GAPDH probe hybridized to an -1.6 kb mRNA species. CRC, calcium release channeL (X-ACTIN GAPDH tients. In contrast to the decreases in CRC and Ca2'-ATPase mRNA abundance in the ICM group, a-actin mRNA abundance (normalized to GAPDH) was not significantly different among the groups with heart failure and was unchanged compared with normal patients ( Table 2 and Figure 2 ). To establish that transfer of RNA did not bias the results obtained by Northern blot analyses, we performed slot blot analyses of CRC mRNA levels normalized to GAPDH mRNA levels on RNA samples from the normal (n=4), ICM (n=4), and IDCM (n=4) groups. There were no significant differences between the densitometric scores of CRC mRNA levels (normalized to GAPDH mRNA levels) obtained by slot blot versus Northern blot analyses (n -12, r=0.995, p<0.01).
Discussion E-C coupling in the heart involves two calcium channels, the DHPR located on the T tubule and the CRC of the SR (reviewed in Reference 28). In the present study, levels of CRC mRNA in the LVs of patients with end-stage heart failure were shown to be decreased by 28% (p<0.025) in those with ICM and increased by 12% (p=NS) in those with IDCM compared with normal patients (Figure 3 and Table 2 ). Of particular interest is the observation that CRC mRNA levels were significantly decreased in patients with ICM but not in those with IDCM, indicating a difference in the expression of CRC mRNA between two forms of end-stage cardiomyopathy. The decreased CRC mRNA levels in the patients with ICM were not caused by a generalized decrease in cardiac gene expression or a decrease in numbers of myocytes in the regions sampled, because the levels of ca-actin were not altered.
In addition to abnormal expression of the CRC of the SR we have shown that expression of the Ca2'-ATPase involved in SR Ca2' reuptake is also affected during end-stage heart failure. In agreement with a previous study in a similar group of patients5 we found that expression of the SR Ca2'-ATPase is decreased. However, in contrast to the CRC, which was decreased only in the ICM group, the SR Ca2'-ATPase was decreased to equivalent levels in both ICM and IDCM groups. Taken together, these data suggest that while reuptake may be altered in both forms of cardiomyopathy, diminished calcium release may be a feature unique to ICM.
While end-stage cardiomyopathies have generally been regarded as a whole in terms of the pathophysiology of myocardial dysfunction, the current data and other recent studies7,29 provide evidence for potentially significant differences at the molecular level between two forms of cardiomyopathy, both of which result in end-stage heart failure. Previous studies have examined the expression of other calcium handling genes in the myocardium in both human end-stage heart failure and in animal models. Expression of the SR Ca2-ATPase is depressed in animal models of cardiac hypertrophy30 32 as well as in human heart failure. To determine the effects of end-stage heart failure on the expression of other genes encoding calcium handling proteins in the heart, we had previously examined the abundance of the cardiac DHPR and calsequestrin transcripts in RNA prepared from the patients examined in the current study.13 Compared with normal subjects the DHPR mRNA was decreased by 47%.13 However, in contrast to the CRC mRNA, no difference was observed between the subgroups with ICM and IDCM in terms of calcium channel expression.
The decreased expression of two calcium channels involved in E-C coupling in the ICM hearts may be related to the abnormal calcium handling of myopathic human cardiac muscle in ischemic heart disease. Defects in calcium handling with regard to E-C coupling might be expected to differ between ICM and IDCM, based on the contrasts in regulation of CRC expression between the two forms of cardiomyopathy.
Differences in the function of components of the f3-adrenergic receptor-G protein-adenylate cyclase complex have been described in ICM versus IDCM subgroups.29 For example, 81-adrenergic receptors were downregulated to a greater extent in dilated versus ischemic cardiomyopathies, but P2-adrenergic receptors showed more uncoupling from adenylate cyclase in the LVs of ischemic myopathic hearts. This study points out that while the clinical features of end-stage heart failure may be similar, irrespective of the etiology of the heart failure, functional differences at the molecular level exist. Regulation of the calcium channels involved in E-C coupling could have significant effects on the performance of the myocardium. Several studies have identified the role of abnormal handling of intracellular IDCM and flux across the plasma membrane. Another possibility is that as the expression of the CRC falls out of proportion to that of the DHPR (in IDCM), an uncoupling of the two channels develops, leading to defective homeostasis of intracellular calcium. Other factors must also be considered, including alterations in myofilament responsiveness to Ca2`.3435
Calcium release channel function might be defective due to alterations in the structure of the channels, abnormal interactions with modulators, and defects in other proteins that may interact with the channel. Elucidation of the possible contribution of these mechanisms requires further study. The present study does not provide data regarding the mechanism of the decreased expression of the CRC in patients with advanced ICM. Although little is known about the regulation of calcium channel gene expression, there is abundant evidence in the case of the DHPR in brain and smooth muscle that different isoforms can be expressed via alternative splicing of the channel mRNA. [36] [37] [38] [39] Alternative splicing has not yet been reported for the CRC. Moreover, growth factors and hormones may play a role in regulating calcium channel gene expression. For example, Marks et a140 have recently shown that expression of the skeletal isoforms of the DHPR and CRC is downregulated by growth factors (specifically, fibroblast growth factors) in a myogenic cell line. Fibroblast growth factors may play a role in regulating calcium channel gene expression in the heart since acidic fibroblast growth factors are expressed and secreted by cardiac myocytes in culture. 41 However, regulation of cardiac calcium channel genes by fibroblast growth factors has not been reported. In another recent study, regulation of the cardiac CRC by thyroid hormone was observed in experimentally induced hyperthyroidism and hypothyroidism in rabbits. 42 Thus, one effect of thyroid hormone on the heart appears to be regulation of calcium channel gene expression. Whether hormonal regulation of calcium channel gene expression plays a role in the adaptations of the heart to end-stage failure remains to be demonstrated. Characterization of the expression of genes encoding proteins involved in E-C coupling in the heart in patients with end-stage heart failure does not permit one to conclude whether the observed differences reflect causative or responsive phenomena. However, the observation that in one case (ICM) mRNA encoding both calcium channels involved in E-C coupling is decreased may have implications in terms of the ability of these hearts to handle calcium and develop contractile force. These observations also may have implications regarding the response of patients with end-stage ICM to pharmacological interventions, including organic calcium channel blockers. For example, patients with decreased expression of both the DHPR and CRC might be expected to respond more profoundly to calcium channel blockers in terms of reduction in contractile force of the LV. However, none of the clinical parameters reported in this study correlated with the observed differences in CRC mRNA levels between the two groups of patients with end-stage heart failure. Thus, clinical identification of patients who might be expected to be more sensitive to therapy with agents that reduce calcium entry (and, hence, calcium-induced calcium release) remains problematic.
One of the most important questions in the present study is whether the observed 28% decrease in CRC mRNA levels in the ICM hearts was caused by an actual decrease in CRC mRNA accumulation or was caused by an artifact of the procedures used to evaluate the RNA samples. We took several measures in this study to establish that equivalent amounts of nondegraded RNA were analyzed for each heart sample. To control for the amounts of RNA bound to nitrocellulose filters, Northern blots were hybridized to both GAPDH and a-actin cDNA probes. CRC mRNA levels in the normal and myopathic ventricles were normalized to both GAPDH and a-actin mRNA levels. The GAPDH probe was used as a control because GAPDH is a constitutively expressed "housekeeping" enzyme that has been used extensively to control for mRNA levels. In the present study we demonstrated that there were no significant differences in the levels of GAPDH mRNA between normal, ICM, and IDCM patients. Arai et a142 had previously directly examined the relation of CRC mRNA regulation to that of GAPDH mRNA in the rabbit heart. In this earlier study GAPDH mRNA levels were used as an internal standard for quantifying the levels of CRC mRNA in hyperthyroid and hypothyroid rabbit hearts. Under conditions in which cardiac CRC mRNA expression was regulated by thyroid hormone, GAPDH mRNA levels were found to be constant.
The actin probe was used as a control to normalize CRC mRNA levels because levels of a-actin mRNA in patients with end-stage heart failure had recently been examined in a study comparing the expression of the skeletal and cardiac actin isoforms. 22 No differences were seen in the expression of a-actin between patients with dilated and ischemic cardiomyopathies. 22 The levels of a-actin mRNA in the myopathic hearts in the present study were also unchanged from those in nor-mal hearts, and there were no significant differences in a-actin mRNA levels between ICM and IDCM ( Figure  3 , Table 2 ). Thus, both GAPDH and a-actin mRNA levels were shown in the present study not to be regulated during end-stage heart failure and thus were suitable for use as internal controls.
The present study is the first to examine CRC mRNA levels in human hearts. For this reason we used Northern blot analyses to demonstrate that the CRC mRNA was a single, nondegraded species in the human heart samples. It is our experience that significant degradation of this large mRNA can be detected (although not quantitated) by observing a smear running down the lane in the Northern blot. We found that the CRC mRNAs were not degraded in the patient samples, and we did not observe any differences in quality of CRC mRNA signals between the normal patients and either group of cardiomyopathic patients (see Figure 1 ). The integrity of the 28s ribosomal RNA band and the ratio of 28s to 18s ribosomal RNAs are generally used as indicators of RNA degradation and were used to monitor the quality (degree of degradation) of the RNA transferred to filters for Northern blot analyses. No significant differences were observed between the transferred RNA for the normal, 1CM, and ICDM samples. To control for the possibility that Northern blot transfer of the large (16 kb) CRC mRNA was not quantitative we also used slot blots (in which no RNA transfer is involved) and showed that the normalized values for CRC mRNA levels were in agreement with those determined from Northern blot analyses (see "Results"). These results indicated that RNA transfer did not bias the quantitation of the CRC mRNA levels. In addition, RNA samples from each type of patient (normal, ICM, and IDCM) were loaded onto each gel to avoid the possibility that inefficient transfer of a particular gel would bias the results. All Northern and slot blots were hybridized to a single labeled probe for each cDNA to r-NL Vol 71, No 1 July 1992 avoid potential differences in signal caused by variabilities in the specific activities of probes labeled at different times. Films were exposed for three different exposure times to ensure that densitometric scanning was performed in the linear range. Taken together, these controls indicated that the significant decrease in CRC mRNA levels in the ICM heart samples were not caused by experimentally introduced artifacts, differences in RNA transfer, or the degree of RNA degradation between the groups of samples studied.
It could be argued that a systematic degradation of CRC mRNA in the ischemic tissues that occurred before sampling (in vivo) might reduce the CRC mRNA levels by 25%. The cause of such in vivo degradation might be a specific decrease in CRC message stability in the ischemic hearts. Either decreased mRNA stability or decreased transcription (or a combination of both) would result in decreased CRC mRNA abundance in the ischemic hearts. A generalized decrease in mRNA stability (i.e., increased mRNA degradation) in the ischemic hearts would have resulted in a decrease in 28s to 18s ribosomal RNA ratios, as well as decreased GAPDH and a-actin mRNA levels, which we did not observe. Alternatively, the CRC mRNA could for some reason have been less stable after the tissue was harvested. This effect would most likely have altered the stability of all large mRNAs, which would have been reflected in a systematic decrease in the ratio of 28s to 18s ribosomal RNAs in the ICM samples, not the CRC mRNA selectively, which we did not observe.
In the present study we have attempted to account for the possibility that in a sampling from the LV wall, different amounts of myocardial cells might be present depending on the extent of fibrosis versus hypertrophy in the hearts. To correct for this possibility we have determined mRNA levels for a-actin that should reflect the myocyte specific mRNA production and correct for any potential loss of myocytes relative to nonmyocytes in the tissue sampled.
This study does not attempt to determine whether the observed decreased expression of the CRC gene is pathogenic for LV dysfunction in patients with endstage heart failure. It is quite possible that this decreased CRC expression is secondary to other, more proximal causes of heart failure. Nevertheless, the decreased levels of CRC mRNA in patients with ischemic cardiomyopathies could lead to altered calcium homeostasis and impaired diastolic and systolic function observed in myopathic human hearts.8 Decreased expression of the CRC might result in a reduction in excitation-contraction coupling leading to decreased contractility.
